ES2165768B1 - Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. - Google Patents

Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.

Info

Publication number
ES2165768B1
ES2165768B1 ES009901580A ES9901580A ES2165768B1 ES 2165768 B1 ES2165768 B1 ES 2165768B1 ES 009901580 A ES009901580 A ES 009901580A ES 9901580 A ES9901580 A ES 9901580A ES 2165768 B1 ES2165768 B1 ES 2165768B1
Authority
ES
Spain
Prior art keywords
sup
sub
group
pharmaceutical compositions
organic group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES009901580A
Other languages
English (en)
Spanish (es)
Other versions
ES2165768A1 (es
Inventor
Forner Dolors Fernandez
Quinones Maria Prat
Albero Maria Antonia Buil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall Prodesfarma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8309225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2165768(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Prodesfarma SA filed Critical Almirall Prodesfarma SA
Priority to ES009901580A priority Critical patent/ES2165768B1/es
Priority to KR1020067027730A priority patent/KR100854315B1/ko
Priority to SK43-2002A priority patent/SK287480B6/sk
Priority to SI200030108T priority patent/SI1200431T1/xx
Priority to DE60001840.7T priority patent/DE60001840T4/de
Priority to DK00951361.5T priority patent/DK1200431T6/en
Priority to AU64330/00A priority patent/AU779881C/en
Priority to HK02103992A priority patent/HK1042487B/en
Priority to KR1020067027733A priority patent/KR100854321B1/ko
Priority to EP00951361.5A priority patent/EP1200431B3/en
Priority to DE60001840A priority patent/DE60001840D1/de
Priority to CA2381165A priority patent/CA2381165C/en
Priority to UA2002010323A priority patent/UA73509C2/uk
Priority to TR2002/00768T priority patent/TR200200768T2/xx
Priority to PL357160A priority patent/PL204024B1/pl
Priority to CZ2002-121A priority patent/CZ304292B6/cs
Priority to IL14753300A priority patent/IL147533A0/xx
Priority to PCT/EP2000/006469 priority patent/WO2001004118A2/en
Priority to BRPI0012434A priority patent/BRPI0012434B8/pt
Priority to AT00951361T priority patent/ATE235492T1/de
Priority to CNB2006100068921A priority patent/CN100451018C/zh
Priority to JP2001509727A priority patent/JP4030040B2/ja
Priority to HU0202100A priority patent/HU228594B1/hu
Priority to ES951361T priority patent/ES2193098T7/es
Priority to PT00951361T priority patent/PT1200431E/pt
Priority to RU2002103605A priority patent/RU2264401C3/ru
Priority to EEP200200017A priority patent/EE04915B3/et
Priority to CNB008127549A priority patent/CN1272334C/zh
Priority to KR1020027000479A priority patent/KR100773844B1/ko
Priority to PE2000000691A priority patent/PE20010397A1/es
Priority to TW089113865A priority patent/TWI284644B/zh
Priority to MYPI20003178 priority patent/MY126959A/en
Priority to EG20000907A priority patent/EG24066A/xx
Priority to CO00052873A priority patent/CO5200759A1/es
Priority to ARP000103613A priority patent/AR029760A1/es
Priority to UY26244A priority patent/UY26244A1/es
Priority to ZA200200232A priority patent/ZA200200232B/xx
Priority to BG106301A priority patent/BG65565B1/bg
Priority to NO20020180A priority patent/NO329484B3/no
Priority to US10/047,464 priority patent/US6750226B2/en
Publication of ES2165768A1 publication Critical patent/ES2165768A1/es
Application granted granted Critical
Publication of ES2165768B1 publication Critical patent/ES2165768B1/es
Priority to US10/740,264 priority patent/US7109210B2/en
Priority to US11/116,777 priority patent/US7078412B2/en
Priority to AU2005202144A priority patent/AU2005202144B2/en
Priority to RU2005121162/04A priority patent/RU2306312C2/ru
Priority to JP2005203365A priority patent/JP4951217B2/ja
Priority to US11/324,919 priority patent/US7214687B2/en
Priority to US11/325,059 priority patent/US7196098B2/en
Priority to US11/636,181 priority patent/US7358260B2/en
Priority to US12/074,929 priority patent/US7750023B2/en
Priority to US12/787,772 priority patent/US7897617B2/en
Priority to US13/011,131 priority patent/US8129405B2/en
Priority to UY0001033494A priority patent/UY33494A/es
Priority to US13/354,873 priority patent/US8513279B2/en
Priority to BE2013C001C priority patent/BE2013C001I2/fr
Priority to CY2013001C priority patent/CY2013001I1/el
Priority to FR13C0001C priority patent/FR13C0001I2/fr
Priority to LU92132C priority patent/LU92132I2/fr
Priority to NO2013002C priority patent/NO2013002I2/no
Priority to US13/939,742 priority patent/US8802699B2/en
Priority to US14/311,102 priority patent/US9056100B2/en
Priority to US14/712,866 priority patent/US9333195B2/en
Priority to US15/019,009 priority patent/USRE46417E1/en
Priority to US15/095,036 priority patent/US9687478B2/en
Priority to US15/599,646 priority patent/US10034867B2/en
Priority to US16/045,333 priority patent/US10588895B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES009901580A 1999-07-14 1999-07-14 Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. Expired - Fee Related ES2165768B1 (es)

Priority Applications (65)

Application Number Priority Date Filing Date Title
ES009901580A ES2165768B1 (es) 1999-07-14 1999-07-14 Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
KR1020067027730A KR100854315B1 (ko) 1999-07-14 2000-07-07 신규한 퀴누클리딘 유도체 및 그것의 무스카린 엠3 수용체리간드로의 이용
SK43-2002A SK287480B6 (sk) 1999-07-14 2000-07-07 Chinuklidínové deriváty, spôsob ich prípravy, liečivé kompozície, ktoré ich obsahujú, a ich použitie
SI200030108T SI1200431T1 (en) 1999-07-14 2000-07-07 Quinuclidine derivatives and their use as muscarinic m3 receptors ligands
DE60001840.7T DE60001840T4 (de) 1999-07-14 2000-07-07 Chinuclidin-derivate und deren verwendung als muscarin-m3-rezeptoren-liganden
DK00951361.5T DK1200431T6 (en) 1999-07-14 2000-07-07 Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
AU64330/00A AU779881C (en) 1999-07-14 2000-07-07 Quinuclidine derivates and their use as muscarinic M3 receptor ligands
HK02103992A HK1042487B (en) 1999-07-14 2000-07-07 Quinuclidine derivatives and their use as muscarinic m3 receptors ligands
KR1020067027733A KR100854321B1 (ko) 1999-07-14 2000-07-07 신규한 퀴누클리딘 유도체 및 그것의 무스카린 엠3 수용체리간드로의 이용
EP00951361.5A EP1200431B3 (en) 1999-07-14 2000-07-07 Quinuclidine derivatives and their use as muscarinic m3 receptors ligands
DE60001840A DE60001840D1 (de) 1999-07-14 2000-07-07 Chinuclidin-derivate und deren verwendung als muscarin-m3-rezeptoren-liganden
CA2381165A CA2381165C (en) 1999-07-14 2000-07-07 Novel quinuclidine derivatives and medicinal compositions containing the same
UA2002010323A UA73509C2 (uk) 1999-07-14 2000-07-07 Хінуклідинові похідні та їх використання як лігандів мускаринового м3-рецептора
TR2002/00768T TR200200768T2 (tr) 1999-07-14 2000-07-07 Yeni kuinüklidin türevleri ve bunu içeren ilaç bileşimleri
PL357160A PL204024B1 (pl) 1999-07-14 2000-07-07 Nowe pochodne chinuklidyny, sposób ich wytwarzania, zastosowanie i zawierające je kompozycje farmaceutyczne
CZ2002-121A CZ304292B6 (cs) 1999-07-14 2000-07-07 Chinuklidinové deriváty, způsob jejich přípravy a použití a farmaceutická kompozice s jejich obsahem
IL14753300A IL147533A0 (en) 1999-07-14 2000-07-07 Novel quinuclidine derivatives and medicinal compositions containing the same
PCT/EP2000/006469 WO2001004118A2 (en) 1999-07-14 2000-07-07 Quinuclidine derivatives and their use as muscarinic m3 receptor ligands
BRPI0012434A BRPI0012434B8 (pt) 1999-07-14 2000-07-07 compostos ésteres de quinuclidina úteis como antagonistas de receptores m3 muscarínicos
AT00951361T ATE235492T1 (de) 1999-07-14 2000-07-07 Chinuclidin-derivate und deren verwendung als muscarin-m3-rezeptoren-liganden
CNB2006100068921A CN100451018C (zh) 1999-07-14 2000-07-07 作为毒蕈碱性m3受体配体的奎宁环衍生物及其用途
JP2001509727A JP4030040B2 (ja) 1999-07-14 2000-07-07 キヌクリジン誘導体およびそれらのムスカリンｍ３レセプターリガンドとしての使用
HU0202100A HU228594B1 (en) 1999-07-14 2000-07-07 Novel quinuclidine derivatives, process for their preparation and medicinal compositions containing the same
ES951361T ES2193098T7 (es) 1999-07-14 2000-07-07 Derivados de quinuclidina y su uso como ligandos de los receptores muscarínicos M3
PT00951361T PT1200431E (pt) 1999-07-14 2000-07-07 Derivados de quinuclidina e sua utilizacao como ligandos de receptores muscarinicos m3
RU2002103605A RU2264401C3 (ru) 1999-07-14 2000-07-07 Производные хинуклидина, способ их получения, фармацевтическая композиция, способ лечения и промежуточные вещества
EEP200200017A EE04915B3 (et) 1999-07-14 2000-07-07 Kinuklidiinderivaadid, nende valmistamismeetod, vaheühendid, farmatseutiline kompositsioon ja nende kasutamine
CNB008127549A CN1272334C (zh) 1999-07-14 2000-07-07 作为毒蕈碱性m3受体配体的奎宁环衍生物及其用途
KR1020027000479A KR100773844B1 (ko) 1999-07-14 2000-07-07 신규한 퀴누클리딘 유도체 및 그것의 무스카린 엠3 수용체리간드로의 이용
PE2000000691A PE20010397A1 (es) 1999-07-14 2000-07-11 Derivados de quinuclidina como antagonistas de receptores muscarinicos m3 y composiciones farmaceuticas que los contienen
TW089113865A TWI284644B (en) 1999-07-14 2000-07-12 Novel quinuclidine derivatives and medicinal compositions containing the same
MYPI20003178 MY126959A (en) 1999-07-14 2000-07-12 Quinuclidine derivatives and their use as muscarinic m3 receptors ligands
EG20000907A EG24066A (en) 1999-07-14 2000-07-12 Novel quinuclidine derivatives and medicinal compositions containing the same
CO00052873A CO5200759A1 (es) 1999-07-14 2000-07-13 Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen
ARP000103613A AR029760A1 (es) 1999-07-14 2000-07-13 Derivados de quinuclidina, proceso para preparar dichos derivados, compuestos intermediarios utilizables en dicho proceso, composiciones farmaceuticas formuladas con dichos derivados y uso de dichos derivados para la produccion de medicamentos para el tratamiento de enfermedades respiratorias, urina
UY26244A UY26244A1 (es) 1999-07-14 2000-07-14 Nuevos derivados de quinuclidina y composiciones farmacéuticas que los contienen.
ZA200200232A ZA200200232B (en) 1999-07-14 2002-01-10 Quinuclidine derivatives and their use as muscarinic M3 receptor ligands.
BG106301A BG65565B1 (bg) 1999-07-14 2002-01-14 Хинуклидинови производни и тяхното използване като мускаринови м3 рецепторни лиганди
NO20020180A NO329484B3 (no) 1999-07-14 2002-01-14 Nye kinuklidinderivater og medisinske sammensetninger inneholdende det samme, samt anvendelse derav for fremstilling av medikamenter
US10/047,464 US6750226B2 (en) 1999-07-14 2002-01-14 Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
US10/740,264 US7109210B2 (en) 1999-07-14 2003-12-17 Quinuclidine derivatives and medicinal compositions containing the same
US11/116,777 US7078412B2 (en) 1999-07-14 2005-04-28 Quinuclidine derivatives and medicinal compositions containing the same
AU2005202144A AU2005202144B2 (en) 1999-07-14 2005-05-18 Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
RU2005121162/04A RU2306312C2 (ru) 1999-07-14 2005-07-06 Производные хинуклидина, фармацевтическая композиция и способ лечения респираторных заболеваний
JP2005203365A JP4951217B2 (ja) 1999-07-14 2005-07-12 キヌクリジン誘導体およびそれらのムスカリンｍ３レセプターリガンドとしての使用
US11/324,919 US7214687B2 (en) 1999-07-14 2006-01-03 Quinuclidine derivatives and medicinal compositions containing the same
US11/325,059 US7196098B2 (en) 1999-07-14 2006-01-03 Quinuclidine derivatives and medicinal compositions containing the same
US11/636,181 US7358260B2 (en) 1999-07-14 2006-12-08 Quinuclidine derivatives and medicinal compositions containing the same
US12/074,929 US7750023B2 (en) 1999-07-14 2008-03-07 Quinuclidine derivatives and medicinal compositions containing the same
US12/787,772 US7897617B2 (en) 1999-07-14 2010-05-26 Quinuclidine derivatives and medicinal compositions containing the same
US13/011,131 US8129405B2 (en) 1999-07-14 2011-01-21 Quinuclidine derivatives and medicinal compositions containing the same
UY0001033494A UY33494A (es) 1999-07-14 2011-07-08 Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen
US13/354,873 US8513279B2 (en) 1999-07-14 2012-01-20 Quinuclidine derivatives and medicinal compositions containing the same
BE2013C001C BE2013C001I2 (enExample) 1999-07-14 2013-01-03
CY2013001C CY2013001I1 (el) 1999-07-14 2013-01-07 Nεα παραγωγα κινουκλιδινης και ιατρικα σκευασματα που τα πepιεχουν
FR13C0001C FR13C0001I2 (fr) 1999-07-14 2013-01-08 Derives de quinuclidine et leur utilisation comme ligands des recepteurs m3 muscariniques
LU92132C LU92132I2 (fr) 1999-07-14 2013-01-16 Sel d'aclidinium avec anion d'un acide mono ou polyvalent pharmaceutiquement acceptable particulièrement le bromure d'aclidinium
NO2013002C NO2013002I2 (no) 1999-07-14 2013-01-18 Aklidiniumsalt med et farmaøytisk akseptabelt anion av en mono-eller polyvalent syre, spesielt aklidiniumbromid
US13/939,742 US8802699B2 (en) 1999-07-14 2013-07-11 Quinuclidine derivatives and medicinal compositions containing the same
US14/311,102 US9056100B2 (en) 1999-07-14 2014-06-20 Quinuclidine derivatives and medicinal compositions containing the same
US14/712,866 US9333195B2 (en) 1999-07-14 2015-05-14 Quinuclidine derivatives and medicinal compositions containing the same
US15/019,009 USRE46417E1 (en) 1999-07-14 2016-02-09 Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
US15/095,036 US9687478B2 (en) 1999-07-14 2016-04-09 Quinuclidine derivatives and medicinal compositions containing the same
US15/599,646 US10034867B2 (en) 1999-07-14 2017-05-19 Quinuclidine derivatives and medicinal compositions containing the same
US16/045,333 US10588895B2 (en) 1999-07-14 2018-07-25 Quinuclidine derivatives and medicinal compositions containing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009901580A ES2165768B1 (es) 1999-07-14 1999-07-14 Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.

Publications (2)

Publication Number Publication Date
ES2165768A1 ES2165768A1 (es) 2002-03-16
ES2165768B1 true ES2165768B1 (es) 2003-04-01

Family

ID=8309225

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009901580A Expired - Fee Related ES2165768B1 (es) 1999-07-14 1999-07-14 Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ES951361T Active ES2193098T7 (es) 1999-07-14 2000-07-07 Derivados de quinuclidina y su uso como ligandos de los receptores muscarínicos M3

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES951361T Active ES2193098T7 (es) 1999-07-14 2000-07-07 Derivados de quinuclidina y su uso como ligandos de los receptores muscarínicos M3

Country Status (39)

Country Link
US (16) US6750226B2 (enExample)
EP (1) EP1200431B3 (enExample)
JP (2) JP4030040B2 (enExample)
KR (3) KR100854315B1 (enExample)
CN (2) CN1272334C (enExample)
AR (1) AR029760A1 (enExample)
AT (1) ATE235492T1 (enExample)
AU (1) AU2005202144B2 (enExample)
BE (1) BE2013C001I2 (enExample)
BG (1) BG65565B1 (enExample)
BR (1) BRPI0012434B8 (enExample)
CA (1) CA2381165C (enExample)
CO (1) CO5200759A1 (enExample)
CY (1) CY2013001I1 (enExample)
CZ (1) CZ304292B6 (enExample)
DE (2) DE60001840D1 (enExample)
DK (1) DK1200431T6 (enExample)
EE (1) EE04915B3 (enExample)
EG (1) EG24066A (enExample)
ES (2) ES2165768B1 (enExample)
FR (1) FR13C0001I2 (enExample)
HK (1) HK1042487B (enExample)
HU (1) HU228594B1 (enExample)
IL (1) IL147533A0 (enExample)
LU (1) LU92132I2 (enExample)
MY (1) MY126959A (enExample)
NO (2) NO329484B3 (enExample)
PE (1) PE20010397A1 (enExample)
PL (1) PL204024B1 (enExample)
PT (1) PT1200431E (enExample)
RU (2) RU2264401C3 (enExample)
SI (1) SI1200431T1 (enExample)
SK (1) SK287480B6 (enExample)
TR (1) TR200200768T2 (enExample)
TW (1) TWI284644B (enExample)
UA (1) UA73509C2 (enExample)
UY (2) UY26244A1 (enExample)
WO (1) WO2001004118A2 (enExample)
ZA (1) ZA200200232B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056100B2 (en) 1999-07-14 2015-06-16 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9254262B2 (en) 2008-03-13 2016-02-09 Almirall, S.A. Dosage and formulation

Families Citing this family (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
AU2001275760B2 (en) 2000-08-05 2005-03-17 Glaxo Group Limited 6.alpha., 9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid S-fluoromethyl ester as an anti-inflammatory agent
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
SK8002003A3 (en) 2000-12-22 2004-05-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
EP1353919B1 (en) * 2000-12-28 2006-07-26 Almirall Prodesfarma AG Novel quinuclidine derivatives and medicinal compositions containing the same
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
HU228508B1 (en) 2001-09-14 2013-03-28 Glaxo Group Ltd Phenethanolamine derivatives and pharmaceutical composition containing them
KR100944580B1 (ko) 2001-12-20 2010-02-25 치에시 파마슈티시 에스.피.아. 1-알킬-1-아조니아비시클로[2.2.2]옥탄 카르바메이트유도체 및 이의 무스카린 수용체 길항제로서의 용도
DE10203753A1 (de) * 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7405224B2 (en) 2002-01-31 2008-07-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
AR040779A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion
TWI295669B (en) 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
CA2511726A1 (en) * 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited Xanthine derivatives as muscarinic receptor antagonists
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
CN100445281C (zh) * 2003-05-02 2008-12-24 诺瓦提斯公司 与毒蕈碱性m3受体结合的奎宁环衍生物
AR044134A1 (es) 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
ATE435862T1 (de) 2003-05-28 2009-07-15 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
EP1644356A1 (en) 2003-07-11 2006-04-12 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
TW200519109A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
UY28417A1 (es) * 2003-07-17 2005-02-28 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
JP2007500150A (ja) * 2003-07-29 2007-01-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とステロイドとの併用剤及び吸入により呼吸障害を治療するためのその使用
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050026886A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
EP1651222A1 (en) * 2003-07-29 2006-05-03 Boehringer Ingelheim International Gmbh Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders
WO2005014044A1 (en) * 2003-07-29 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising betamimetics and an anticholinergic
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
WO2005013994A1 (en) * 2003-07-31 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising anticholinergics and a betamimetic
ES2358673T3 (es) 2003-10-14 2011-05-12 Glaxo Group Limited Antagonistas de receptores de acetilcolina muscarínicos.
AP2006003575A0 (en) * 2003-10-17 2006-04-30 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists.
TW200524577A (en) * 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
GB0329182D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US20090253908A1 (en) * 2004-03-11 2009-10-08 Glaxo Group Limited Novel m3 muscarinic acetylchoine receptor antagonists
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
JP2007529513A (ja) 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
MY144753A (en) 2004-04-27 2011-10-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005112644A2 (en) * 2004-05-13 2005-12-01 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
CA2569074C (en) * 2004-05-31 2012-12-18 Almirall Prodesfarma S.A. Combinations comprising antimuscarinic agents and pde4 inhibitors
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP1765809B1 (en) * 2004-06-16 2008-12-31 Ranbaxy Laboratories Limited Xanthine derivatives useful as muscarinic receptor antagonists
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
GB0418278D0 (en) 2004-08-16 2004-09-15 Glaxo Group Ltd Medicament dispenser
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
ATE517908T1 (de) 2005-01-10 2011-08-15 Glaxo Group Ltd Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
EP1858554A2 (en) * 2005-03-09 2007-11-28 Boehringer Ingelheim International GmbH New pharmaceutical compositions based on anticholinergics and pde 5-inhibitors
UY29440A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
US20090298802A1 (en) 2005-03-30 2009-12-03 Sequeira Joel A Pharmaceutical Compositions
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007016639A2 (en) * 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
TW200738634A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
US20080234315A1 (en) * 2005-08-02 2008-09-25 Jakob Busch-Petersen M3 Muscarinic Acetylcholine Receptor Antagonists
JP2009504624A (ja) 2005-08-08 2009-02-05 アージェンタ ディスカバリー リミテッド ビシクロ［２．２．１］ヘプタ−７−イルアミン誘導体およびその使用
EP1937068A4 (en) * 2005-08-18 2010-08-04 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
NZ567124A (en) 2005-10-21 2011-08-26 Novartis Ag Human antibodies against Interleukin-13 and therapeutic uses to treat asthma
PE20071068A1 (es) 2005-12-20 2007-12-13 Glaxo Group Ltd Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
EP1978955A1 (en) * 2006-01-06 2008-10-15 Boehringer Ingelheim International GmbH New pharmaceutical compositions based on anticholinergics and andolast
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EA200801997A1 (ru) 2006-04-20 2009-04-28 Глаксо Груп Лимитед Новые соединения
JP5373599B2 (ja) 2006-04-21 2013-12-18 ノバルティス アーゲー アデノシンａ２ａ受容体アゴニストとして使用するためのプリン誘導体
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
EP2043717A1 (en) * 2006-07-14 2009-04-08 Astra Zeneca AB Inhalation system and delivery device for the administration of a drug in the form of dry powder
KR20090030347A (ko) 2006-07-19 2009-03-24 아스트라제네카 아베 신규 트리시클릭 스피로피페리딘 화합물, 이들의 합성 및 이들의 케모킨 수용체 활성의 조절제로서의 용도
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
AU2007302263A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as P13K lipid kinase inhibitors
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
GB0622827D0 (en) 2006-11-15 2006-12-27 Glaxo Group Ltd Sheet driver for use in a drug dispenser
US20100112061A1 (en) * 2006-12-13 2010-05-06 William Baker Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis
JP2010515729A (ja) 2007-01-10 2010-05-13 アイアールエム・リミテッド・ライアビリティ・カンパニー チャネル活性化プロテアーゼ阻害剤としての化合物および組成物
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
RU2484821C2 (ru) * 2007-02-21 2013-06-20 Альмираль, С.А. Новые способы
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
EP2332933A1 (en) 2007-05-07 2011-06-15 Novartis AG Epithelial sodium channel (ENaC) inhibitors
HRP20110938T1 (hr) 2007-09-07 2012-01-31 Theravance Spojevi koji sadrže gvanidin i koji se koriste kao agonisti muskarinskih receptora
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
EP2444120B1 (en) 2007-12-10 2017-09-27 Novartis AG Spirocyclic amiloride analogues as ENac blockers
WO2009079392A1 (en) 2007-12-14 2009-06-25 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
GB2468073B (en) 2008-02-26 2012-09-05 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
GB0808707D0 (en) * 2008-05-13 2008-06-18 Argenta Discovery Ltd New compounds 275
CA2723981A1 (en) 2008-05-13 2009-11-19 Astrazeneca Ab New compounds 273
MX2010012814A (es) 2008-05-23 2010-12-20 Amira Pharmaceuticals Inc Inhibidor de proteina activadora de 5-lipoxigenasa.
JP5607032B2 (ja) 2008-05-27 2014-10-15 アストラゼネカ・アクチエボラーグ フェノキシピリジニルアミド誘導体およびｐｄｅ４仲介疾患状態におけるその使用
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
ES2566339T3 (es) 2008-06-05 2016-04-12 Glaxo Group Limited Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
CA2727196A1 (en) 2008-06-10 2009-12-17 Novartis Ag Organic compounds
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
EP2406255B1 (en) 2009-03-09 2015-04-29 Glaxo Group Limited 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Ｉｔｋ阻害剤として使用されるピリミジン誘導体
EA201171144A1 (ru) 2009-03-19 2012-04-30 Мерк Шарп Энд Домэ Корп. ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
EP2408915A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120004282A1 (en) 2009-03-27 2012-01-05 Merck Sharp & Dohme Corp, RNA Interference Mediated Inhibition of the Intercellular Adhesion Molecule 1 (ICAM-1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
EP2411018A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
EP2411516A1 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2010233772B2 (en) 2009-04-09 2014-04-24 Novartis Ag Process for preparing pyrrolidinium salts
EP2421835A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited N-pyrazolyl carboxamides as crac channel inhibitors
JP2012524754A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド Ｃｒａｃチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド
JO3025B1 (ar) 2009-04-30 2016-09-05 Glaxo Group Ltd الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3
DK2435023T3 (en) 2009-05-29 2016-10-24 Pearl Therapeutics Inc Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta 2-adrenergic receptor agonists and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0910537D0 (en) 2009-06-18 2009-07-29 Ivax Pharmaceuticals Ireland Inhaler
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
CN102573846B (zh) 2009-08-17 2015-10-07 因特利凯公司 杂环化合物及其用途
KR20120089463A (ko) 2009-08-20 2012-08-10 노파르티스 아게 헤테로시클릭 옥심 화합물
EP2813227A1 (en) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0919465D0 (en) 2009-11-06 2009-12-23 Norton Healthcare Ltd Airflow adaptor for a breath-actuated dry powder inhaler
US20120238559A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Novel compounds
EP2507223A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
US8735390B2 (en) 2010-09-08 2014-05-27 Glaxosmithkline Intellectual Property Development Limited Polymorphs and salts
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
WO2012052459A1 (en) 2010-10-21 2012-04-26 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
JP5795643B2 (ja) 2010-10-21 2015-10-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
MX2013009767A (es) 2011-02-25 2013-10-01 Irm Llc Compuestos y composiciones como inhibidores de trk.
EP2683716A1 (en) 2011-03-11 2014-01-15 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
US20150297604A1 (en) 2012-04-03 2015-10-22 Novartis Ag Combination Products with Tyrosine Kinase Inhibitors and their Use
EP2666465A1 (en) 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
HK1212986A1 (zh) * 2012-12-05 2016-06-24 奇斯药制品公司 作为pde4-抑制剂的苯基乙基吡啶衍生物
AU2013363837A1 (en) 2012-12-17 2015-06-11 Almirall, S.A. New use of aclidinium
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
ES2712988T5 (es) 2013-03-15 2022-10-21 Pearl Therapeutics Inc Métodos y sistemas para acondicionamiento de materiales cristalinos en partículas
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
BR112016000629B1 (pt) * 2013-07-13 2023-10-31 Beijing Showby Pharmaceutical Co., Ltd. Compostos de quinina e isômeros ópticos, método de preparação e utilização médica dos mesmos
MY184292A (en) 2013-09-22 2021-03-30 Sunshine Lake Pharma Co Ltd Substituted aminopyrimidine compounds and methods of use
WO2015055690A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
EP3057588A1 (en) 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
CZ306791B6 (cs) * 2013-10-29 2017-07-12 Zentiva, K.S. Průmyslově využitelný způsob přípravy aklidinium bromidu o vysoké čistotě
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
CN103755699A (zh) * 2014-01-06 2014-04-30 万特制药(海南)有限公司 一种2-羟基-2,2-二噻吩-2-基乙酸-1-氮杂二环[2,2,2]辛-3(r)-基酯制备方法
CN103755698A (zh) * 2014-01-06 2014-04-30 万特制药(海南)有限公司 一锅法制备阿地溴铵的工艺
CZ2014188A3 (cs) 2014-03-26 2015-10-07 Zentiva, K.S. Nové formy aclidinium chloridu a způsob jejich přípravy
AU2015235880B2 (en) 2014-03-28 2018-11-01 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
BR112016023967A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de pirazina como inibidores de fosfatidilinositol 3-cinase
AU2014391605A1 (en) 2014-04-24 2016-10-27 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
CA2948441A1 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
AU2016227080B2 (en) * 2015-03-02 2019-10-03 Ltt Bio-Pharma Co., Ltd. Quinuclidine derivative
PT108370B (pt) * 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
WO2016162878A1 (en) * 2015-04-04 2016-10-13 Harman Finochem Limited An advantageous process for preparing 1-azoniabicyclo[2.2.2]octane,3-[(hydroxydi-2-thienylacetyl)oxy]-1-(3¬phenoxypropyl)-, bromide, (3r)- and its novel crystalline form-i
CZ2015257A3 (cs) 2015-04-16 2016-10-26 Zentiva, K.S. Způsob pro zmenšování velikosti částic bromidu [(3R)-1-(3-fenoxypropyl)chinuklidin-1-ium-3-yl] 2-hydroxy-2,2-bis(2-thienyl)acetátu
CN105085355B (zh) * 2015-06-25 2017-11-14 御盛隆堂药业有限责任公司 一种取代的吡咯烷羧酸酯类化合物及其制备方法和应用
WO2017044434A1 (en) 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2018029126A1 (en) 2016-08-08 2018-02-15 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2018094392A1 (en) 2016-11-21 2018-05-24 Lupin Inc. Medicament dispenser
GB201700727D0 (en) 2017-01-16 2017-03-01 Teva Pharma Inhalers and airflow adaptors therefor
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
US20190076607A1 (en) 2017-09-13 2019-03-14 Lupin Atlantis Holdings Sa Inhaler and mesh for an inhaler
JP7254076B2 (ja) 2017-11-19 2023-04-07 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換ヘテロアリール化合物及び使用方法
WO2019129801A1 (en) 2017-12-28 2019-07-04 Linnea S.A. Process for the purification of methyl-2,2-dithienylglycolate
CA3083040A1 (en) 2018-01-20 2019-07-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
WO2020058823A1 (en) 2018-09-17 2020-03-26 Lupin, Inc. Dose indicator assembly for a medicament dispenser
BR112021024668A2 (pt) 2019-06-10 2022-05-31 Novartis Ag Derivado de piridina e pirazina para o tratamento de fc, dpoc e bronquiectasia
AR119819A1 (es) 2019-08-28 2022-01-12 Novartis Ag Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
EP4126139A1 (en) 2020-03-25 2023-02-08 Lupin Inc. Multi-carrier medicament dispensers
JP2023519585A (ja) 2020-03-26 2023-05-11 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ウイルス感染を予防または治療するカテプシン阻害剤
EP4185997A1 (en) 2020-07-23 2023-05-31 Lupin Inc. Dose counter assemblies for medicament dispensers

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091570A (en) 1960-08-08 1963-05-28 Lakeside Lab Inc Antidepressant: 3-pyrrolidyl glycolates
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
FR2414044A1 (fr) 1978-01-10 1979-08-03 Pharmindustrie Nouveaux derives d'aza-1 bicyclo(2,2,2) octane, utilisables comme medicaments
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
IT1116047B (it) 1979-04-27 1986-02-10 Sigma Tau Ind Farmaceuti Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
FR2539135B1 (fr) 1983-01-11 1986-02-28 Essilor Int Hydrogels de polyurethane et procede de fabrication
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GB8613811D0 (en) 1986-06-06 1986-07-09 Phares Pharm Res Nv Composition & method
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
US4675326A (en) * 1985-05-08 1987-06-23 Gabriel Amitai Bisquaternary antidotes
US4855290A (en) 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
GB8718345D0 (en) * 1987-08-03 1987-09-09 Fordonal Sa N-substituted benzamides
US4843074A (en) 1988-05-17 1989-06-27 Marion Laboratories, Inc. 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
US5290815A (en) 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
GB8923590D0 (en) * 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
US5507281A (en) 1990-08-30 1996-04-16 Boehringer Ingelheim Kg Device for initiating a mechanical switching operation in synchronism with the breathing
EP0500864B1 (en) 1990-09-06 2001-09-19 Pfizer Limited Antimuscarinic bronchodilators
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
WO1992004928A2 (en) 1990-09-26 1992-04-02 Pharbita B.V. Inhaler devices provided with a reservoir for several doses of medium for inhaling, transporting device, whirl chamber
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
US5290539A (en) 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5263480A (en) 1991-02-01 1993-11-23 Cyberonics, Inc. Treatment of eating disorders by nerve stimulation
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DE4108393A1 (de) 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US6299863B1 (en) 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
GB9119705D0 (en) * 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic compounds
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
ES2129117T3 (es) 1992-12-09 1999-06-01 Boehringer Ingelheim Pharma Formulaciones en disolucion en forma de aerosol medicinales estabilizadas.
KR0163472B1 (ko) 1992-12-18 1998-11-16 에릭 에스. 딕커 분말 약품용 흡입기
WO1995021820A1 (en) 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US5569447A (en) * 1994-04-19 1996-10-29 The United States Of America Represented By The Secretary Department Of Health And Human Services Stannylated 3-quinuclidinyl benzilates and methods of preparing radiohalogenated derivatives
US5773485A (en) 1994-07-29 1998-06-30 Minnesota Mining And Manufacturing Company Acrylic syrup curable to a crosslinked viscoelastomeric material
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
BR9604977A (pt) 1995-04-14 1998-06-09 Glaxo Wellcome Inc Inalador de dose medida sistema inalador de dose medida e uso do mesmo
CN1181896C (zh) 1995-06-21 2004-12-29 索福泰克两合公司 带整体计量装置的药筒和药粉吸入器
AU6392496A (en) 1995-06-29 1997-01-30 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
DE19528145A1 (de) 1995-08-01 1997-02-06 Boehringer Ingelheim Kg Neue Arzneimittel und ihre Verwendung
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
US5846983A (en) 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US6150415A (en) 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US5885834A (en) 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
FR2756739B1 (fr) 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
DK1087750T3 (da) 1998-06-18 2004-01-26 Boehringer Ingelheim Pharma Farmaceutiske formuleringer til aerosoler med to eller flere aktive stoffer
US6423298B2 (en) 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
ITMI981671A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
US6475467B1 (en) 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations
US5962505A (en) 1998-08-31 1999-10-05 Bobrove; Arthur M. Method for treating hot flashes in humans
DE19847968A1 (de) 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
GB9902689D0 (en) 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20040002548A1 (en) 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) * 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
SE9902935D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
GB9928311D0 (en) 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6410563B1 (en) 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
FR2803378B1 (fr) 1999-12-29 2004-03-19 Valeo Climatisation Echangeur de chaleur a tubes a plusieurs canaux, en particulier pour vehicule automobile
EP1258253A1 (en) 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
JP2003522165A (ja) 2000-01-31 2003-07-22 ファイザー・プロダクツ・インク Ｐｄｅ４アイソザイムの阻害剤として有用なピリミジンカルボキサミド
EP1270577B1 (en) 2000-03-23 2006-12-06 Takeda Pharmaceutical Company Limited Furoisoquinoline derivatives, process for producing the same and use thereof
GB0008485D0 (en) 2000-04-07 2000-05-24 Glaxo Group Ltd Pharmaceutical compositions
GB0009606D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009592D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009605D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
US6777132B2 (en) 2000-04-27 2004-08-17 Valence Technology, Inc. Alkali/transition metal halo—and hydroxy-phosphates and related electrode active materials
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
ME00220B (me) 2000-05-22 2010-10-10 Chiesi Farm Spa Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom
US20020052312A1 (en) 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
AR029984A1 (es) 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
US6706726B2 (en) 2000-10-14 2004-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics which may be used as medicaments as well as processes for preparing them
US6852728B2 (en) 2000-10-14 2005-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them
DE10062712A1 (de) 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
US6608054B2 (en) 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
US20020183292A1 (en) 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
US20020137764A1 (en) 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20020122773A1 (en) 2000-12-20 2002-09-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and dopamine agonists
CA2733294C (en) 2000-10-31 2011-12-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical combination of a tiotropium salt and ciclesonide
US20020151541A1 (en) 2000-10-31 2002-10-17 Michel Pairet Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
US20020193393A1 (en) 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US20030158196A1 (en) 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US6620438B2 (en) 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
DE10056104A1 (de) 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
US20020193392A1 (en) 2000-11-13 2002-12-19 Christel Schmelzer Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
US20100310477A1 (en) 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
SK8002003A3 (en) 2000-12-22 2004-05-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
EP1353919B1 (en) 2000-12-28 2006-07-26 Almirall Prodesfarma AG Novel quinuclidine derivatives and medicinal compositions containing the same
US20020189610A1 (en) 2001-02-01 2002-12-19 Karl-Heinz Bozung Pharmaceutical compositions containing an ipratropium salt and a betamimetic
US20020179087A1 (en) 2001-02-01 2002-12-05 Karl-Heinz Bozung Pharmaceutical compositions containing an oxitropium salt and a betamimetic
DE10104367A1 (de) 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Betamimetika enthaltende Arzneimittelkompositionen mit geringeren Nebenwirkungen
DE10104370A1 (de) 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Arzneimittelkompositionen mit geringeren Nebenwirkungen
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030216329A1 (en) 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
CN1511042A (zh) 2001-05-25 2004-07-07 治疗阻塞性气道疾病的pde4抑制剂与抗胆碱能剂的组合
EP1397135B1 (en) 2001-05-25 2006-12-06 Boehringer Ingelheim Pharma GmbH & Co.KG Combination of a pde4 inhibitor and tiotropium or derivative thereof for treating obstructive airways
GB0115181D0 (en) 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
US6919325B2 (en) 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
US6680345B2 (en) 2001-09-14 2004-01-20 Boehringer Ingelheim Pharma Kg Salicylic acid salts of salmeterol
MXPA04002401A (es) 2001-09-14 2004-05-31 Boehringer Ingelheim Pharma Nuevos medicamentos para inhalacion.
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
US6974803B2 (en) 2001-12-06 2005-12-13 Pfizer Inc Pharmaceutical combination
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US6790856B2 (en) 2002-01-31 2004-09-14 Boehringer Ingelheim Pharma Kg Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments
GB0202635D0 (en) 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
CN100398094C (zh) 2002-03-01 2008-07-02 奇斯药制品公司 福莫特罗超细制剂
US6756508B2 (en) 2002-03-04 2004-06-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Cinnamic acid salts, processes for their preparation, and their use as medicaments
DE10216429A1 (de) 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
DE10216333A1 (de) 2002-04-13 2003-10-30 Boehringer Ingelheim Pharma Neue Carbonsäureester mit anticholonerger Wirksamkeit, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7094788B2 (en) 2002-04-13 2006-08-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
BR0310084A (pt) 2002-05-17 2005-02-15 Novartis Ag Composição farmacêutica compreendendo um inibidor de renina, um bloqueador de canal de cálcio e um diurético
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
US20040058950A1 (en) 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
ES2211315B1 (es) 2002-11-12 2005-10-16 Almirall Prodesfarma, S.A. Nuevos compuestos triciclicos.
PL375631A1 (en) 2002-11-27 2005-12-12 Altana Pharma Ag Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
DE10307759B3 (de) 2003-02-19 2004-11-18 Schering Ag Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel
EP1452179A1 (en) 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US20040184995A1 (en) 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
US20060189642A1 (en) 2003-03-28 2006-08-24 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
PL1610787T3 (pl) 2003-03-28 2008-07-31 Astrazeneca Ab Synergiczna kombinacja zawierająca roflumilast i środek antycholinergiczny wybrany z soli tiotropium do leczenia chorób układu oddechowego
EP1651222A1 (en) 2003-07-29 2006-05-03 Boehringer Ingelheim International Gmbh Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders
US20050026948A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050026887A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
JP2007500150A (ja) 2003-07-29 2007-01-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とステロイドとの併用剤及び吸入により呼吸障害を治療するためのその使用
WO2005014044A1 (en) 2003-07-29 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising betamimetics and an anticholinergic
US20050026886A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
US20050025718A1 (en) 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
WO2005013994A1 (en) 2003-07-31 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising anticholinergics and a betamimetic
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
WO2005074918A1 (en) 2004-02-06 2005-08-18 Benzstrasse 1 D-61352 Bad Homburd The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
ATE541570T1 (de) 2004-02-06 2012-02-15 Meda Pharma Gmbh & Co Kg Kombination von anticholinergika und hemmern von phosphodiesterase typ 4 zur behandlung von atemwegserkrankungen
ES2309705T3 (es) 2004-02-06 2008-12-16 MEDA PHARMA GMBH & CO. KG Nueva combinacion de anticolinergico y beta-mimeticos para el tratamiento de enfermedades respiratorias.
US7712077B2 (en) * 2004-02-27 2010-05-04 International Business Machines Corporation Method and system for instantiating components conforming to the “COM” specification in custom contexts
ES2239546B1 (es) 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
DE102004016179A1 (de) 2004-03-30 2005-10-20 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von proliferativen Prozessen
CA2569074C (en) 2004-05-31 2012-12-18 Almirall Prodesfarma S.A. Combinations comprising antimuscarinic agents and pde4 inhibitors
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
US20090298802A1 (en) 2005-03-30 2009-12-03 Sequeira Joel A Pharmaceutical Compositions
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
CL2008000500A1 (es) 2007-02-19 2008-09-05 Cipla Ltd Combinacion farmaceutica que comprende una combinacion de dos o mas broncodilatadores o una combinacion de al menos un broncodilatador y al menos un corticosteroide; uso para tratar o prevenir una enfermedad respiratoria; e inhalador que comprende di
RU2484821C2 (ru) 2007-02-21 2013-06-20 Альмираль, С.А. Новые способы
EP2165159B1 (en) 2007-07-03 2013-07-17 Nxp B.V. Calibration of an amr sensor
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
EP2666465A1 (en) * 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
AU2013363837A1 (en) 2012-12-17 2015-06-11 Almirall, S.A. New use of aclidinium

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056100B2 (en) 1999-07-14 2015-06-16 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9333195B2 (en) 1999-07-14 2016-05-10 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9254262B2 (en) 2008-03-13 2016-02-09 Almirall, S.A. Dosage and formulation

Also Published As

Publication number Publication date
CY2013001I2 (el) 2015-10-07
SK287480B6 (sk) 2010-11-08
RU2005121162A (ru) 2007-01-20
DE60001840T3 (de) 2015-10-08
BG106301A (en) 2002-08-30
FR13C0001I1 (enExample) 2013-01-03
JP2003504368A (ja) 2003-02-04
CN1373760A (zh) 2002-10-09
US20170319557A1 (en) 2017-11-09
HUP0202100A2 (en) 2002-10-28
CO5200759A1 (es) 2002-09-27
FR13C0001I2 (fr) 2013-11-01
US20030055080A1 (en) 2003-03-20
US9056100B2 (en) 2015-06-16
WO2001004118A3 (en) 2001-07-19
BE2013C001I2 (enExample) 2019-05-21
HUP0202100A3 (en) 2003-09-29
US8513279B2 (en) 2013-08-20
ES2165768A1 (es) 2002-03-16
US20080221155A1 (en) 2008-09-11
ES2193098T3 (es) 2003-11-01
DK1200431T6 (en) 2015-09-28
US6750226B2 (en) 2004-06-15
DK1200431T3 (da) 2003-07-21
IL147533A0 (en) 2002-08-14
US20120122826A1 (en) 2012-05-17
US20100234333A1 (en) 2010-09-16
PL357160A1 (en) 2004-07-12
CY2013001I1 (el) 2015-10-07
EP1200431B3 (en) 2015-06-24
CZ2002121A3 (cs) 2002-11-13
EE04915B1 (et) 2007-10-15
JP2005350476A (ja) 2005-12-22
UY26244A1 (es) 2000-12-29
KR20070009744A (ko) 2007-01-18
RU2306312C2 (ru) 2007-09-20
BRPI0012434B8 (pt) 2021-05-25
US20060106056A1 (en) 2006-05-18
JP4951217B2 (ja) 2012-06-13
US7196098B2 (en) 2007-03-27
US20140303126A1 (en) 2014-10-09
DE60001840T4 (de) 2015-11-26
DE60001840T2 (de) 2003-12-11
PL204024B1 (pl) 2009-12-31
CN1824664A (zh) 2006-08-30
EE200200017A (et) 2003-04-15
US20130310353A1 (en) 2013-11-21
NO20020180D0 (no) 2002-01-14
AU2005202144A1 (en) 2005-06-09
PT1200431E (pt) 2003-07-31
NO20020180L (no) 2002-03-13
KR20070007396A (ko) 2007-01-15
RU2264401C3 (ru) 2018-06-01
AR029760A1 (es) 2003-07-16
KR100854321B1 (ko) 2008-08-26
TWI284644B (en) 2007-08-01
LU92132I2 (fr) 2013-03-18
TR200200768T2 (tr) 2002-07-22
US7358260B2 (en) 2008-04-15
USRE46417E1 (en) 2017-05-30
WO2001004118A2 (en) 2001-01-18
AU2005202144B2 (en) 2007-06-14
US20160296503A1 (en) 2016-10-13
JP4030040B2 (ja) 2008-01-09
SI1200431T1 (en) 2003-10-31
KR100854315B1 (ko) 2008-08-26
ATE235492T1 (de) 2003-04-15
US20050209272A1 (en) 2005-09-22
US7078412B2 (en) 2006-07-18
US8129405B2 (en) 2012-03-06
CA2381165F (en) 2001-01-18
AU6433000A (en) 2001-01-30
NO2013002I2 (no) 2013-09-09
NO329484B1 (no) 2010-10-25
UA73509C2 (uk) 2005-08-15
US20150246026A1 (en) 2015-09-03
CN1272334C (zh) 2006-08-30
CA2381165A1 (en) 2001-01-18
BR0012434A (pt) 2002-04-02
EG24066A (en) 2008-05-08
ZA200200232B (en) 2003-04-10
UY33494A (es) 2013-04-05
ES2193098T7 (es) 2012-12-13
SK432002A3 (en) 2003-04-01
US8802699B2 (en) 2014-08-12
US20040132768A1 (en) 2004-07-08
EE04915B3 (et) 2016-07-15
US7109210B2 (en) 2006-09-19
PE20010397A1 (es) 2001-04-11
US9333195B2 (en) 2016-05-10
BG65565B1 (bg) 2008-12-30
US10588895B2 (en) 2020-03-17
US20110118223A1 (en) 2011-05-19
DE60001840D1 (de) 2003-04-30
AU779881B2 (en) 2005-02-17
CZ304292B6 (cs) 2014-02-19
DK1200431T5 (da) 2005-01-31
US10034867B2 (en) 2018-07-31
NO329484B3 (no) 2013-04-29
US7897617B2 (en) 2011-03-01
RU2264401C2 (ru) 2005-11-20
US20070099953A1 (en) 2007-05-03
EP1200431B1 (en) 2003-03-26
NO2013002I1 (no) 2013-02-11
KR100773844B1 (ko) 2007-11-06
CN100451018C (zh) 2009-01-14
US7750023B2 (en) 2010-07-06
HU228594B1 (en) 2013-04-29
EP1200431A2 (en) 2002-05-02
KR20020021155A (ko) 2002-03-18
US20190183867A1 (en) 2019-06-20
CA2381165C (en) 2009-10-27
BRPI0012434B1 (pt) 2016-03-22
US9687478B2 (en) 2017-06-27
MY126959A (en) 2006-11-30
HK1042487B (en) 2003-07-18

Similar Documents

Publication Publication Date Title
ES2165768B1 (es) Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ECSP034672A (es) Derivados de quinuclidina novedosos y composiciones medicinales que los contienen
ES2061471T5 (es) Derivados de la piridina, compuestos farmaceuticos que comprenden la misma, su utilizacion para la fabricacion de medicamentos con valor terapeutico o preventivo y procedimiento para su fabricacion.
ES2083569T3 (es) Nuevos derivados de ariletenileno y procedimiento para su preparacion.
ES2158778B1 (es) Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen.
MX9704777A (es) Compuestos espiro tetraciclicos, procedimiento para su preparacion y composiciones que los contienen.
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
ZA919181B (en) Oxazolopyridine derivatives,processes for preparing these and pharmaceutical compositions containing them
KR950000676A (ko) 신규 설포닐아미노 피리미딘
AR038419A1 (es) Derivados de piridina y quinolina
CO5080747A1 (es) Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p
ES2174579T3 (es) Nuevos derivados benzotiofenicos, benzofuranicos e indolicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
KR860005778A (ko) 나프탈렌 유도체의 제조방법
RU2003121236A (ru) Арилированные амиды фуран- и тиофенкарбоновых кислот с блокирующим калиевый канал действием
MX9207335A (es) Nuevos derivados del acido fosfonosuccinico, procesos para su preparacion y composicion farmaceuticas que los contiene.
ES2096685T3 (es) Composicion que contiene colorantes del tipo rodacianina para el tratamiento del cancer.
GB853799A (en) Diquaternary compounds and process of preparing same
ES2045189T3 (es) Nuevos agentes anti-arritmicos i.
NO952402L (no) Substituerte 6-azaandrostenoner
ES2153019T3 (es) Derivados de benzo-dioxano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
MX9306529A (es) Derivados de pirazol condensado, metodo para fabricarlos y composicion farmaceutica que los contiene
ATE62225T1 (de) Tryptamin-derivate, ihre herstellung und anwendung in heilmitteln.
ES2131300T3 (es) Derivados triciclicos y composiciones farmaceuticas que los contienen.
EP1404652A4 (en) NEW ALKALOID DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
ES2183492T3 (es) Nuevos derivados de nitrono,su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020316

Kind code of ref document: A1

Effective date: 20020316

FG2A Definitive protection

Ref document number: 2165768B1

Country of ref document: ES

FD1A Patent lapsed

Effective date: 20100315